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The periaqueductal gray (PAG) region of the midbrain has been implicated in both stimulation-produced and opioid- 
induced analgesia. High-affinity p-selective opioid-binding sites associated with p type opioid receptors have been de- 
tected in rat PAG-enriched P2 membranes, and these receptors have been shown to be coupled to guanine nucleotide- 
binding proteins (G-proteins). In the present study the potential G-protein-mediated coupling of p type opioid receptors 
to the inhibition of adenylyl cyclase was examined utilixing in vitro adenylyl cyclase assays. In the presence of Na+, opioid 
agonists inhibited adenylyl cyclase in a p selective, naloxone reversible, dose dependent, and pertussis toxin sensitive man- 
ner. Overall the data suggests that p type opioid receptors in the rat PAG are coupled to G-protein-mediated inhibition 
of adenylyl cyclase. 
Opioid receptor; G-protein; Adenylyl cyclase 
1. INTRODUCTION 
The periaqueductal gray (PAG) region of the 
midbrain has been implicated in both stimulation- 
produced and opioid-induced analgesia. Both 
focal electrical stimulation within and in- 
tracerebral microinjection of opioids into the PAG 
result in a profound analgesia unaccompanied by 
general motor or behavioral depression [1,2]. It 
appears that this opioid-induced analgesia in the 
PAG is opioid receptor mediated in that it is 
stereoselective, dose dependent, and reversed by 
the specific opioid antagonist naloxone [3]. In ad- 
dition it appears that opioid agonism within the 
midbrain is important if not essential for the 
mediation of the analgesia observed after systemic 
administration of analgesic opioids since the 
analgesia produced by typical systemic doses of 
morphine can also be reversibly attenuated by in- 
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tracerebroventricular microinjection of naloxone 
into the third ventricle and the vicinity of the PAG 
in a dose-dependent manner [4]. 
The heterogeneity of opioid receptors is now 
widely accepted. /I, X, S, and E type opioid recep- 
tors have been postulated on the basis of phar- 
macological data in the chronic spinal dog [5] and 
in in vitro guinea pig ileum, mouse vas deferens, 
and rat vas deferens preparations [6,7]. High- 
affinity ,u-, x- and S-selective opioid-binding sites 
have also been subsequently identified in brain 
tissue [g-lo]. However in vitro radioligand- 
binding studies utilizing homogenized rat PAG 
tissue have identified only high-affinity ,u-selective 
opioid-binding sites in membrane from this par- 
ticular rat brain region. High-affinity 6- and X- 
selective opioid binding was not detected [Ill. Ad- 
ditional binding and biochemical studies utilizing 
rat PAG membranes have provided strong 
evidence that these high-affinityp-selective opioid- 
binding sites are associated with functional ,U type 
opioid receptors, and that these receptors are 
coupled to guanine nucleotide-binding proteins (G- 
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proteins) in a manner similar to the coupling of 
other hormone and neurotransmitter cell surface 
receptors to G-proteins [ 121. 
Such G-proteins are known to mediate the 
coupling of hormone and neurotransmitter cell 
surface receptors to a number of different signal 
transduction, second messenger effector systems 
[ 131. In the NG-108,15 neuroblastoma-glioma cell 
line, a hybrid cell line which expresses only a single 
type of opioid receptor, agonism at S opioid recep- 
tors is coupled to the inhibition of adenylyl cyclase 
activity via a G-protein [14]. It is the purpose of 
this study to determine if agonist binding at the,u 
type opioid receptors of the rat PAG are similarly 
coupled to the adenylyl cyclase signal transduction 
effector system. 
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2. METHODS 
2.1. Membrane preparation 
Male Sprague-Dawley rats weighing 180-200 g were used in 
all experiments. Rats were killed by decapitation, and the brain 
minus cerebellum were immediately dissected over ice. The 
PAG region of the midbrain of each rat was initially isolated by 
three transverse cuts along the main cerebral axis; the first cut 
caudal to the corpus callosum, the second cut between the 
superior and inferior colliculi, and the third cut caudal to the 
inferior colliculi. PAG tissue was further concentrated by 
removing the white matter surrounding the visible gray matter 
in the central region of the two inner transverse sections produc- 
ed by the three previous transverse cuts. The individually 
isolated PAG regions were pooled, washed in ice-cold 10 mM 
Hepes/0.32 M sucrose/l.6 mM EGTA buffer (pH 7.4), and 
homogenized in a Teflon-glass homogenizer. The homogenate 
was centrifuged at 1000 x g for 10 min. The supernatant was 
saved and the pellet resuspended in buffer and again centrifug- 
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Fig. 1. Effects of DAGO on basal adenylyl cyclase activity in the presence of Na+. The data are expressed as percent change in activity 
relative to the basal adenylyl cyclase activity of non-opioid-treated controls. Each column represents the mean of triplicate 
determinations. F = 3.50449532, p < 0.055. Basal activity = 45.04 + 3.07 pmol [32P]cAMP/min per mg protein. 
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ed at 1000 x g for 10 min. This pellet was discarded and the 
pooled supernatant from both 1000 x g spins was centrifuged 
at 22500 x g for 20 min. The resulting pellet was resuspended 
in buffer and again centrifuged at 22500 x g for 20 min. The 
final Pz pellet was resuspended in 10 mM Hepes/l.6 mM 
EGTA buffer @H 7.4), and frozen in ahquots for future use. 
Typically the PAG-enriched PZ membrane was resuspended to 
and stored in an average protein concentration of 4.8 mg/ml, 
as determined by the Lowry assay [ 151. Thawed PAG-enriched 
PZ membrane was used once and never refrozen. 
2.2. Pertussis toxin pretreatment of membrane 
PAG-enriched Pz membrane was pretreated with pertussis 
toxin utilizing a modified version of a technique described by 
Kurose et al. [14]. Pertussis toxin was first activated with 
100 mM dithiothreitol for 4 h at room temperature. Membrane 
was incubated with various concentrations of pertussis toxin in 
a reaction mixture containing 50 mM Tris buffer (pH 8), 
20 mM thymidine, 0.5 mM ATP, 20 mM GTP, 5 mM MgClz, 
1 mM EDTA, 5 mM dithiothreitol, 20 mM creatinc phosphate, 
10 U of creatine phosphokinase, 1 mM l,lO-O-phenanthroline, 
and 1 mM NAD at room temperature for 1 h. The ADP- 
ribosylation reaction was terminated with the addition of 250 ~1 
of ice-cold 25 mM Hepes buffer (pH 7.4), and the samples were 
centrifuged at 850 x g for 15 min. The resulting pellet was 
resuspended to an appropriate protein concentration in 10 mM 
Hepes/l.B mM EGTA buffer (pH 7.4) for immediate use in 
adenylate cyclase assays. 
2.3. Adenylyi cyclase assay 
Adenylyl cyclase activity in PAG-enriched Pz membranes was 
assayed via the formation of [32P]cAMP utilizing a modified 
version of the technique described by White and Karr [16]. The 
reaction mixture of each adenylyl cyclase assay consisted of 
10 mM MgClz, 40 mM creatine phosphate, 2 mM CAMP, 10 U 
of creatine phosphokinase, 40 mM GTP, 20 mM theophylline, 
2 mM l,lO-0-phenanthroline, 100 mM NaCl where ap- 
propriate, 40 mM Hepes buffer (pH 7.4), and various concen- 
trations of opioid agonists and antagonists to a total volume of 
50 ~1. The reaction mixture was incubated with 25 pl of PAG- 
enriched P2 membrane for IO min at 0°C. Each sample contain- 
ed 43.5 or 62.5 Fg of protein. The reaction was initiated with 
the addition of 20 ~1 of a [a-32P]ATP solution. The final con- 
centration of ATP per assay was 0.1 mM, and each assay con- 
tained 1 pCi of [~u-~~P]ATP. he reaction was terminated with 
the addition of 150~1 of 1 M HC104. 
10000 cpm of [‘HIcAMP was added to each sample as an in- 
ternal standard for CAMP recovery. Reaction product CAMP 
was separated from other labeled compounds with double col- 
umns of Dowex and alumina as described by White and Karr 
[16]. Collected CAMP was placed in individual counting vials, 
scintillation cocktail was added, and the vials were counted. All 
assays were carried out in triplicate. One way analysis of 
variance and unpaired Student’s t-tests were utilized in 
statistical analysis. 
3. RESULTS 
A 10 /IM concentration of the ,u selective opioid 
agonist [D-Ala’&methyl-Phe4,Glyo15]enkephalin 
(DAGO) significantly inhibited both basal and 
forskolin-stimulated adenylyl cyclase activity in 
PAG-enriched PZ membranes. The DAGO inhibi- 
tion of forskolin-stimulated adenylyl cyclase ac- 
tivity was not consistently dose dependent, was not 
naloxone reversible, and the opioid antagonist 
naloxone itself significantly inhibited forskolin- 
stimulated adenylyl cyclase activity, even when 
present in low concentration (data not shown). 
DAGO inhibition of basal adenylyl cyclase ac- 
tivity was also not consistently dose dependent. 
However, the DAGO inhibition of basal adenylyl 
cyclase activity was naloxone reversible, although 
naloxone itself did not significantly affect adenylyl 
cyclase activity (data not shown). 
In the presence of 100 mM NaCl, DAGO did in- 
hibit basal adenylyl cyclase activity in a more dose- 
dependent manner with borderline statistical 
significance. In the presence of 100 mM NaCl 
DAGO inhibition of adenylyl cyclase activity was 
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Fig.2. Effects of DAGG, DPDPE, and U50,488H on basal 
adenylyl cyclase activity in the presence of Na’. The data are 
expressed as percent change in activity relative to the basal 
adenylyl cyclase activity of non-opioid-treated controls. Each 
column represents the mean of triplicate determinations. Basal 
activity = 58.05 f 2.47 pmol [32P]cAMP/min per mg protein. 
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Fig.3. Effects of DAGO on basal adenylyl cyclase actjvity in the 
presence of Na+ following pertussis toxin pretreatment of 
membrane. The data are expressed as percent change in activity 
relative to the basal adenylyl cyclase activity of non-opioid- 
treated controls. Each column represents the mean of triplicate 
determinations. Basal activity after 0, 1.0, 5.0, and 10.0 pg/ml 
pertussis toxin pretreatment = 57.71 + 0.89, 65.07 + 0.65, 
60.49 f 0.74, and 56.99 f 2.44 pmol [32P]cAMP/min per mg 
protein respectively. 
naloxone reversible. The results are shown in fig. 1. 
This effect is also selective for opioid agonists with 
a reported p profile. Neither the J-selective opioid 
agonist [D-Pen’,D-Per?]enkephalin (DPDPE) nor 
the x-selective opioid agonist trans-3,4-dichloro- 
N-methyl-N-[2-(l-pyrrolidinyl)cyclohexyl]benzene- 
acetamide, methane sulfonate, hydrate 
(U50,488H) affected basal adenylyl cyclase activity 
to a significant extent. The results are shown in 
fig.2. 
Pretreatment of PAG-enriched PZ membranes 
with activated pertussis toxin abolished DAGO in- 
hibition of adenylyl cyclase activity. This effect 
was reproducible but not consistently dose depen- 
dent. The results are shown in fig.3. 
4. DISCUSSION 
The plant-derived diterpine forskolin is believed 
to directly stimulate the catalytic component of 
adenylyl cyclase and is commonly used in the study 
of the adenylyl cyclase enzyme system. Forskolin is 
a particularly useful tool in the study of the inhibi- 
tion of adenylyl cyclase in that its presence within 
an adenylyl cyclase assay produces a higher degree 
of enzyme activity against which an inhibitory 
signal may be more easily detectable. However the 
use of forskolin in the study of opioid inhibition of 
adenylyl cyclase activity in PAG-enriched Pz mem- 
branes may be undesirable. 
The p-selective opioid agonist DAGO inhibits 
adenylyl cyclase activity in PAG-enriched Pz mem- 
branes in what initially may seem to be a confusing 
manner. Both basal and forskolin-stimulated 
adenylyl cyclase activity are significantly inhibited, 
but in the presence of forskolin DAGO inhibition 
of adenylyl cyclase activity is neither dose depen- 
dent nor naloxone reversible. Surprisingly, nalox- 
one itself significantly inhibits forskolin- 
stimulated adenylyl cyclase activity, also in a non- 
dose-dependent manner. In contrast, DAGO in- 
hibition of basal adenylyl cyclase activity is na- 
loxone reversible, and in the absence of forskolin 
naloxone itself does not significantly affect ade- 
nylyl cyclase activity. It is possible that naloxone 
somehow interferes with the forskolin stimulation 
of adenylyl cyclase in a manner unrelated to its an- 
tagonism of opioid receptors. Such interference of 
forskolin stimulation of adenylyl cyclase would ap- 
pear as inhibition of this enzyme. 
Although high doses of DAGO significantly in- 
hibit basal adenylyl cyclase activity in PAG- 
enriched PZ membranes in the absence of for- 
skolin, such DAGO inhibition is also not con- 
sistently dose dependent. However in the presence 
of Na+, a cation which has been shown to be re- 
quired in the coupling of opioid receptors to G- 
proteins and adenylyl cyclase in the NG-108,15 
neuroblastoma-glioma cell line [ 18,191, DAGO 
does inhibit basal adenylyl cyclase activity in both 
a naloxone reversible and consistent dose- 
dependent manner. It is possible that in the 
presence of 100 mM NaCl opioid receptors are 
more efficiently coupled to the inhibition of 
adenylyl cyclase in the PAG. 
The presence of Na+ and the absence of for- 
skolin are assay conditions which probably more 
closely approximate physiological conditions. 
Under such conditions DAGO inhibits adenylyl 
cyclase in PAG-enriched Pz membranes in a man- 
ner which is consistent with G-protein-mediated 
coupling of opioid receptors to this enzyme. In the 
presence of Na+ and the absence of forskolin 
DAGO inhibition of adenylyl cyclase is not only 
apparently dose dependent and clearly naloxone 
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reversible, but is also p opioid agonist selective. S 
and x opioid agonists do not significantly affect 
adenylyl cyclase activity. In addition after pretreat- 
ment of PAG-enriched PZ membranes with a suffi- 
cient concentration of activated pertussis toxin, 
DAGO does not significantly inhibit adenylyl 
cyclase activity. While this effect of pertussis toxin 
pretreatment is not entirely consistent it suggests 
the involvement of G-proteins in the observed 
DAGO inhibition of adenylyl cyclase activity in 
PAG membranes. 
The maximal effect of DAGO on adenylyl 
cyclase activity is small, in the range of 15% to 
20%, but it is statistically significant, reproduci- 
ble, and consistent from tissue preparation to 
tissue preparation regardless of the amount of 
basal activity measured. 
Opioid agonists have previously been shown to 
inhibit adenylyl cyclase activity in homogenized rat 
striatal tissue, but this inhibition is believed to 
result from agonist activity at 6 type opioid recep- 
tors as in the NG-IO&J,15 neuroblastoma-glioma 
cell line [20,21]. Overall the adenylyl cyclase assay 
data presented in this study provide evidence that 
p type opioid receptors of the PAG can also couple 
to adenylyl cyclase to inhibit the production of the 
second messenger CAMP. This finding is consistent 
with a report that /I opioid receptors in rat 7315~ 
pituitary tumor cells are also coupled to the inhibi- 
tion of adenylyl cyclase via G-proteins [22]. The 
coupling of p opioid receptors to additional G- 
protein-mediated effector systems is possible and 
warrants further study. 
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